1. Home
  2. Applications
  3. Cardiotoxicity Screening

Cardiotoxicity Screening

Axol’s iPSC-derived cardiomyocytes are CiPA-validated, making them the perfect model for cardiotoxicity assays.

Human Relevant Cardiotox with iPSC-Derived Cardiomyocytes

Pre-clinical cardiotoxicity testing is being transformed by CiPA-validated iPSC-derived cardiomyocytes


Quality, robust human iPSC-derived cells for cardiotoxicity testing

The Comprehensive in vitro Pro-Arrhythmia Assay (CiPA) initiative was introduced to develop a new strategy for assessing cardiac safety of compounds in vitro.

Axol’s human iPSC-derived cardiomyocytes are CiPA-validated, making them a suitable model for screening compounds for cardiotoxicity.

Reach out to learn more about our iPSC-derived cardiomyocytes, and the in house services we offer to aid your R&D

Application Request



Assay Development

Axol’s iPSC-derived cells are robust and reproducibly made, making them the perfect tool for your assay development requirements.


Co-Culture Models

Axol’s iPSC-derived cells can be grown in co-culture to provide a more physiologically relevant scenario for cellular development and function.